Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-004346-42
    Sponsor's Protocol Code Number:3150-301-008
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-05-24
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2018-004346-42
    A.3Full title of the trial
    A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Crohn's Disease
    Studio multicentrico, randomizzato, in doppio cieco, con doppio mascheramento, controllato con principio attivo e placebo, di fase 2b/3 senza soluzione di continuità, a gruppi paralleli della durata di 52 settimane volto a valutare l'efficacia e la sicurezza di brazikumab in partecipanti con malattia di Crohn attiva da moderata a grave
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
    Uno studio con controllo attivo e placebo su Brazikumab in soggetti con Morbo di Crohn da moderatamente a gravemente attiva
    A.3.2Name or abbreviated title of the trial where available
    52-Week Phase 2b/3 Crohn's Disease Study
    Uno studio di fase 2b/3 sul Morbo di Chron della durata di 52 settimane
    A.4.1Sponsor's protocol code number3150-301-008
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03759288
    A.5.4Other Identifiers
    Name:INDNumber:111,773
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorALLERGAN LIMITED
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAllergan Sales LLC
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAllergan Ltd.
    B.5.2Functional name of contact pointCTRG
    B.5.3 Address:
    B.5.3.1Street AddressGround Floor, Marlow International, The Parkway
    B.5.3.2Town/ cityMarlow, Buckinghamshire
    B.5.3.3Post codeSL7 1YL
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number000000
    B.5.5Fax number000000
    B.5.6E-mailML-CTRG@Allergan.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBrazikumab
    D.3.2Product code [Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Huma
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBRAZIKUMAB
    D.3.9.1CAS number 1610353-18-8
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameAnti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody; previously referred to as MEDI2070 and AMG 139, AGN-151-598
    D.3.9.4EV Substance CodeSUB188673
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number70
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Humira®
    D.2.1.1.2Name of the Marketing Authorisation holderAbbVie Deutschland GmbH Co. KG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNA
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNADALIMUMAB
    D.3.9.1CAS number 331731-18-1
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeSUB20016
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeAnticorpo monoclonale
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBrazikumab
    D.3.2Product code [Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Huma
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBRAZIKUMAB
    D.3.9.1CAS number 1610353-18-8
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameAnticorpo monoclonale umano anti-Interleuchina-23 Immunoglobulina G2 (IgG2); precedentemente denominato MEDI2070 e AMG 139
    D.3.9.4EV Substance CodeSUB188673
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number120
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboConcentrate for solution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    D.8 Placebo: 3
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Crohn's Disease
    Morbo di Crohn
    E.1.1.1Medical condition in easily understood language
    Crohn's disease is a disease that causes the intestines to become swollen and may develop ulcers
    Il morbo di Crohn è una malattia che causa gonfiore a livello intestinale e che può portare allo sviluppo di ulcere
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10011402
    E.1.2Term Crohn's disease (colon)
    E.1.2System Organ Class 100000004856
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10011402
    E.1.2Term Crohn's disease (colon)
    E.1.2System Organ Class 100000004856
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Stage 1: To compare the efficacy of brazikumab with that of placebo to achieve endoscopic response and clinical remission at Week 12
    Stage 2: To compare the efficacy of brazikumab with that of Humira® to achieve endoscopic response and clinical remission at Week 52 in participants who are BM+
    Fase 1: confrontare l'efficacia di brazikumab con quella del placebo per ottenere una risposta endoscopica e una remissione clinica alla settimana 12
    Fase 2: confrontare l'efficacia di brazikumab con quella di Humira® per ottenere risposta endoscopica e remissione clinica alla settimana 52 nei partecipanti che sono BM+
    E.2.2Secondary objectives of the trial
    Stage 1:
    To compare the efficacy of brazikumab with that of placebo to achieve sustained endoscopic response and clinical remission at both Wk12 and Wk52
    To compare the efficacy of brazikumab with that of placebo to achieve endoscopic remission and clinical remission at Wk52
    To compare the efficacy of brazikumab with that of placebo to achieve endoscopic response at Week 12 and endoscopic remission at Wk52 and clinical remission at both Wk12 and Wk52
    Stage 2:
    To compare the efficacy of brazikumab with that of Humira® to achieve sustained endoscopic response and clinical remission at both Wk12 and Wk52 in participants who are BM+
    To compare the efficacy of brazikumab with that of Humira® to achieve endoscopic remission and clinical remission at Wk52 in participants who are BM+
    To compare the efficacy of brazikumab with that of Humira® to achieve CS free (for the last 12 wks before the assessment at Wk 52) endoscopic and clinical remission at Wk 52 in participants who are BM+
    Fase 1:Per confrontare l'efficacia di brazikumab con quella del placebo per ottenere una risposta endoscopica sostenuta e una remissione clinica sia alla sett 12 che alla sett 52
    Per confr l'eff di brazikumab con quella del plb per ottenere la remiss endosc e la remiss clinica alla sett 52
    Per confr l'eff di brazikumab con quella del plb per ottenere la risp endosc alla sett 12 e la remiss endosc alla sett 52 e la remiss clin sia alla sett 12 che alla sett 52
    Fase 2:Per confrontare l'efficacia di brazikumab con quella di Humira® per ottenere una risposta endosc sostenuta e una remiss clin sia alla sett 12 che alla sett 52 nei partec che sono BM+
    Per confr l'effic di brazikumab con quella di Humira® per ottenere la remiss endosc e la remiss clin alla sett 52 nei partecip che sono BM+
    Per confr l'effic di brazikumab con quella di Humira® per ott assenza di sintomi clin (per le ultime 12 sett prima della valut alla sett 52), remiss endoscopica e clin alla sett 52 nei partec che sono BM+
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Aged 16 to 80 years, inclusive, or minimum age of adult consent according to local regulations, at Screening. For participants less than 18years of age, the participant must weigh at least 40 kg at Screening.
    2. Diagnosis of ileal, ileocolonic, or colonic CD with an onset of symptoms for a minimum of 3 months prior to Screening as determined by the investigator based on clinical history, exclusion of other etiologies including infectious causes, and characteristic endoscopic and/or histologic findings.
    3. Moderately to severely active CD
    4. Participant had an inadequate response or intolerance to intervention with oral CS, azathioprine, methotrexate, or 6- mercaptopurine, or demonstrated CS dependence for the treatment of CD.
    5. Participants taking 5-aminosalicylates, Oral prednisone (or equivalent), Budesonide, Immunomodulators, Oral antibiotics, Probiotics must be at a stable dose.
    6. Meets the following TB criteria: Participant has no known history of active TB; Participant has no known history of latent TB without completion of an appropriate course of intervention or is presently taking appropriate ongoing prophylactic intervention; Meets 1 of the following acceptable TB test results: Negative QFT-TB obtained from central laboratory within 4 weeks prior to randomization or For a positive QFT-TB test obtained during Screening from the central laboratory, active TB must be ruled out or Indeterminate QFT-TB test obtained during the Screening period from the central laboratory with ongoing QFT-TB testing; A negative tuberculin skin test is required if the QFT-TB test is not approved/registered in that country; Participants with a history of using anti-TNFa agents for a treatment course of 1 year or longer who have discontinued an anti-TNFa agent within 6 months prior to Screening must obtain a chest x-ray showing no evidence of active TB
    within 8 weeks prior to Screening or during Screening.
    7. Females of childbearing potential who are sexually active with a nonsterilized male partner must use 2 acceptable methods of contraception from Screening.
    8. Female participants who are post-menopausal and of non-childbearing potential must have an elevated FSH at or above the range for postmenopausal women by the central laboratory during Screening.
    9. Nonsterilized males who are sexually active with a female partner of childbearing potential must comply with the methods of contraception
    10. Ability to provide written informed consent prior to any study procedures
    11. Willingness and ability to attend all study visits, comply with the study procedures, read and write in order to complete questionnaires, and be able to complete the study period
    1. Età compresa tra 16 e 80 anni, inclusi, o età minima per il consenso degli adulti secondo le normative locali, al momento dello screening. Per i partecipanti di età inferiore ai 18 anni, il partecipante deve pesare almeno 40 kg allo Screening.
    2. Diagnosi di CD ileale, ileocolonica o colonica con un insorgenza di sintomi per almeno 3 mesi prima dello screening come determinato dallo sperimentatore sulla base della storia clinica, esclusione di altre eziologie, incluse cause infettive e caratteristiche endoscopiche e/o istologiche scoperte.
    3. CD da moderatamente a severamente attiva
    4. Il partecipante ha avuto una risposta inadeguata o intolleranza all'intervento con CS orale, azatioprina, metotrexato o 6- mercaptopurina o dimostrata dipendenza da CS per il trattamento del CD.
    5. I partecipanti che assumono 5-aminosalicilati, prednisone orale (o equivalente), Budesonide, immunomodulatori, antibiotici orali, i probiotici devono essere a una dose stabile.
    6. Soddisfa i seguenti criteri TB: il partecipante non ha una storia nota di TB attiva; Il partecipante non ha una storia conosciuta di TB latente senza il completamento di un appropriato corso di intervento o sta attualmente prendendo un adeguato intervento profilattico in corso; Soddisfa uno dei seguenti risultati del test TB accettabile: TB QFT negativa ottenuta dal laboratorio centrale entro 4 settimane prima della randomizzazione o per un test QFT-TB positivo ottenuto durante lo screening dal laboratorio centrale, deve essere esclusa la TB attiva o il QFT-TB test indeterminato ottenuto durante il periodo di Screening dal laboratorio centrale con test QFT-TB in corso; Un test cutaneo alla tubercolina negativo è richiesto se il test QFT-TB non è approvato / registrato in quel paese; I partecipanti con una storia di uso di agenti anti-TNFa per un ciclo di trattamento di 1 anno o più che hanno interrotto un agente anti-TNFa entro 6 mesi prima dello Screening devono ottenere una radiografia del torace che non mostra alcuna evidenza di TB attiva entro 8 settimane prima dello screening o durante lo screening.
    7. Le donne in età fertile che sono sessualmente attive con un partner maschile non sterilizzato devono utilizzare 2 metodi contraccettivi accettabili da Screening.
    8. Le partecipanti donne in post-menopausa e in età non fertile devono avere un FSH elevato o superiore all'intervallo per le donne in postmenopausa da parte del laboratorio centrale durante lo Screening.
    9. I maschi non sterilizzati che sono sessualmente attivi con una partner femminile in età fertile devono rispettare i metodi contraccettivi
    10. Capacità di fornire il consenso informato scritto prima di qualsiasi procedura di studio
    11. Disponibilità e capacità di frequentare tutte le visite di studio, rispettare le procedure di studio, leggere e scrivere per completare i questionari ed essere in grado di completare il periodo di studio
    E.4Principal exclusion criteria
    1. Partic has previously received Humira® and was intolerant to treat or had met the crit for prim or second non-resp to treat:
    a. Primary non-resp: Signs and symptoms of persistently active disease despite a history of at least 1 induct regimen of H® per the local label consisting of at least 2 doses at least 2 w apart
    b. Second non-resp: Recurrence of sympt of persistently active dis during scheduled maint dosing of H® per the local label following prior clinical benefit
    c. Intol: AE associated with discontinuation of H® therapy, including, but not limited to, hypersensitivity, infusion-related reaction, inf, or congestive HF
    2. Partic is unable or unwilling to have endoscopic proced performed during the study.
    3. History or current diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, colonic mucosal dysplasia, primary sclerosing cholangitis, or untreated bile acid malabsorption.
    4. History of toxic megacolon within 3 m prior to Basel (V 2).
    5. Any intra-abdominal surgery, bowel resection, diversion, placement of ostomy or stoma within 3 m prior to Screening. Particip with a draining stoma are excluded.
    6. Partic has an enterocutaneous or entovesicular fistula. Particip with active fistulas may be considered if there is no anticipation for surgery and there is no evidence of active infection (eg,
    abscess) after further discussion with the study MM.
    7. Bowel perforation during the 6 m prior to Screening or evidence of obstruction within 3 m of Screening.
    8. Complications of CD including short bowel syndr, strictures/stenoses with obstruction or pre-stenotic dilation, or cond where surgery may be anticipated within 6 m, or other cond that may confound efficacy eval for the study.
    9. Partic has any non-passable colonic stenosis/narrowing identified during the qualifying ileocolonoscopy (success endoscope passage to the caecum with inability to enter the endoscope into the ileum is not covered under this exclus criterion, and does not require
    exclus).
    10. Ongoing nutrit dependency for total parenteral nutrit or an elemental diet at Screening.
    11. Partic has any of the following related to inf:
    a. Evid of a recent (within 6 m of Basel [V 2]) systemic fungal inf, requiring inpatient hospit, and/or antifungal treatment. Partic treated for localized fungal infections (eg, oral, vaginal, and skin candidiasis, onychomycosis) are not excluded.
    b. Any inf requiring hosp or treat with IV antiinfectives (including anti-viral treat) within 4 w of Screening
    c. CMV or EBV infection that has not completely resolved within 8 w prior to Screening
    d. Clin significant chronic inf (eg, osteomyelitis) that has not resolved within 8 w of Screening
    e. Non-serious infect requiring oral anti-infectives within 2 w prior to random must be further discussed with the study MM. Chronic suppressive antiviral treatment for HSV in the absence of active lesions or uncomplicated urinary tract infections are not considered exclusionary.
    f. Partic has clin evidence of or suspected to have an abscess during Screening. Cutaneous and perianal/perirectal abscesses are not exclusionary if drained and adequately treated at least 3 w prior to Screening.
    g. Diagnosis of peritonitis or receiving treat for peritonitis within 8 w prior to Screening
    h. Partic has any underlying condition that predisposes partic to infections
    12. Previous allogenic bone marrow transplant or history of organ or cell-based transpl (eg, islet cell transpl or autologous stem cell transpl) with the exception of corneal transpl.
    13. Chronic hep B or C inf, TB, or C. difficile-pos at Screening (V 1).
    14. Known history of primary immunodef, splenectomy, or any underlying condition that predisposes the subject to infect, including HIV infection. Partic with pos results of HIV testing by the cen lab will be excl.
    15. Prior history of or current diagn of a demyelinating disorder.
    All exc crit cannot be list in this field, please refer to the s 5.2 of the prot
    1. Il partec ha già ricevuto Humira® ed è stato intoll al trattam o ha soddisf i criteri di non risp primaria o sec al tratt:
    a. Non risp prim: segni e sintomi di mal persistentemente att nonost una storia di almeno 1 regime di induz di Humira® per etichetta locale consistente in almeno 2 dosi a distanza di almeno 2 sett
    b. Non risp sec: ricorrenza dei sintomi di mal persistentemente attiva durante il dosaggio program di mant di Humira® secondo l'etichetta locale a seguito di un prec benef clin
    c. Intoll: esposiz assoc alla sosp della terapia con Humira®, inclusa, a titolo esemplificativo ma non esaustivo, ipersensibilità, reaz correlata all'infus, infez o insuff cardiaca congestizia
    2. Il partecip non è in grado o non vuole eseguire proc endoscopiche durante lo studio.
    3. Storia o diagnosi attuale di colite ulc, colite indet, colite microscopica, colite ischemica, displasia della muc del colon, colangite sclerosante primitiva o malass di acido biliare non tratt.
    4. Storia di megacolon tossico nei 3 m prec il basale (visita 2).
    5. Qls interv chir intra-addom, resez intest, deviaz, posiz di stomia o stomia entro 3 m prima dello screening. I partec con uno stoma drenante sono escl.
    6. Il partec ha una fistola enterocutanea o entovesicolare. I partec con fistole att possono essere considerati se non vi è alcuna aspett per la chir e non vi sono prove di infez attiva (ad es.ascesso) dopo un'ulteriore discuss con il MM dello studio.
    7. perforaz dell'intest durante i 6 m prec allo screening o prova di ostruz entro 3 m dallo screening.
    8. Complicaz di CD comprendenti sindr dell'intest corto, stenosi/stenosi con ostruzione o dilataz pre-stenotica, o condiz in cui la chir può essere anticipata entro 6 m, o altre condiz che possono confondere le valutaz di eff per lo studio.
    9. Il partec ha stenosi/restringimento del colon non percettibili identificati durante la ileocolonoscopia qualific (il pass dell'endoscopio con successo al cieco con incapacità di entrare nell'endoscopio nell'ileo non è coperto da questo criterio di escl e non richiede escl).
    10. Dip nutriz continua per la nutriz parenterale tot o una dieta elem allo Screening.
    11. Il partec ha una delle seguenti condiz relative alle infez:
    a. Prove di una infez fungina sist recente (entro 6 m dall'interv basale [Visita 2]), che richiede il ricovero osped e/o il tratt antifungino. I partec trattati per infez fungine localizz (ad es., Candidosi orale, vaginale e cutanea, onicomicosi) non sono esclusi.
    b. Qls infez che richieda il ricovero in osp o il tratt con antinfettivi IV (incl tratt anti-virale) entro 4 sett dallo Screening
    c. Infez da virus CMV o Epstein-Barr che non si è complet risolta entro 8 sett prima dello screening
    d. Infez cronica clinicam signif (ad es. Osteomielite) che non si è risolta entro 8 sett dallo Screening
    e. L'infez non grave che richiede l'uso di antinfettivi per via or entro 2 sett prima della randomizz deve essere ult discussa con il MM dello studio. Il tratt antivirale soppressivo cronico per il virus HSV in ass di lesioni att o infez del tratto ur non complicate non è cons escludente.
    f. Il partec ha evid clin o sosp di avere un ascesso durante lo screening. Gli ascessi cutanei e perianali/perirettali non sono escludenti se drenati e adeg trattati alm 3 sett prima dello Screening.
    h. Il partec ha una condiz di base che predispone il partec alle infez
    12. Prec trap di mid oss allogenico o storia di trap di organi o cell (ad es. trap di cell insulari o trap di cell stam autologhe) ad ecc del trap di cornea.
    13. Infez cronica da v dell'epatite B o C, TB o C. diff allo screening (visita 1).
    14. Storia nota di immunodef primaria, splenectomia o qualsiasi condiz sottostante che predisponga il sogg all'infez, comp l'infez da HIV. Saranno esclusi i partec con risultati pos del test HIV da parte del lab cent.
    15. Storia preg o diag attuale di una mal demielinizzante.
    Tutti i crit di escl non poss essere elencati in questo campo, fare rif alla sez 5.2 del prot
    E.5 End points
    E.5.1Primary end point(s)
    Stage 1:
    a. Endoscopic response
    b. Clinical remission
    Stage 2:
    a. Endoscopic response
    b. Clinical remission
    Fase 1:
    a. Risposta endoscopica
    b. Remissione clinica
    Fase 2:
    a. Risposta endoscopica
    b. Remissione clinica
    E.5.1.1Timepoint(s) of evaluation of this end point
    Stage 1:
    a. at Week 12: Minimum of 50% decrease from Baseline in SES-CD total score
    b. at Week 12: Average daily LSF subscore of = 3 as assessed on the CDAI LSF item AND
    Average daily AP subscore of = 1 as assessed on the CDAI AP item
    Stage 2:
    a. at Week 52
    b. at Week 52
    Fase 1:
    a. alla settimana 12: diminuzione di un minimo del 50% dal Baseline nel punteggio totale SES-CD
    b. alla settimana 12: media giornaliera LSF subscore di = 3 come stabilito nell'elemento CDAI LSF
    E
    media giornaliera AP subscore di = 1 come stabilito dall'elemento CDAI AP
    Fase 2:
    a. alla settimana 52
    b. alla settimana 52
    E.5.2Secondary end point(s)
    Stage 1:
    a. Endoscopic response
    b. Clinical remission
    c. Endoscopic remission
    d. Clinical remission
    e. Endoscopic response and endoscopic remission
    f. Clinical remission
    Stage 2:
    a. Endoscopic response
    b. Clinical remission
    c. Endoscopic remission
    d. Clinical remission
    e. CS-free endoscopic remission
    f. CS-free clinical remission
    Fase 1:
    a. Risposta Endoscopica
    b. Remissione clinica
    c. Remissione Endoscopica
    d. Remissione clinica
    e. Risposta Endoscopica e Remissione Endoscopica
    f. Remissione clinica
    Fase 2:
    a. Risposta Endoscopica
    b. Remissione clinica
    c. Remissione endoscopica
    d. Remissione clinica
    e. Remissione endoscopica libera da sintomi clinici
    f. Remissione clinica libera da sintomi clinici
    E.5.2.1Timepoint(s) of evaluation of this end point
    Stage 1:
    a. at both Week 12 and Week 52
    b. at both Week 12 and Week 52
    c. at Week 52
    - SES-CD total score of 0-2 OR
    - SES-CD total score of = 4 and at least 2-point reduction from
    Baseline with no
    subscore > 1
    d. at Week 52
    e. at Week 12 and at Week 52
    f. at both Week 12 and Week 52
    Stage 2:
    a. at both Week 12 and Week 52.
    b. at both Week 12 and Week 52
    c. at Week 52
    d. at Week 52
    e. at Week 52
    f. at Week 52
    Fase 1:
    a. a entrambe le settimane 12 e 52
    b. a entrambe le settimane 12 e 52
    c. alla settimana 52
    - SES-CD punteggio totale di 0-2 O
    - SES-CD punteggio totale = 4 e almeno 2-punti di riduzione dal Baseline senza subscore > 1
    d. alla settimana 52
    e. a entrambe le settimane 12 e 52
    f. a entrambe le settimane 12 e 52
    Fase 2:
    a. a entrambe le settimane 12 e 52.
    b. a entrambe le settimane 12 e 52
    c. alla settimana 52
    d. alla settimana 52
    e. alla setimana 52
    f. alla settimana 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Double Dummy, operativamente senza soluzione di continuità
    Double Dummy, Operationally Seamless
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned19
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA180
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Israel
    Russian Federation
    South Africa
    Ukraine
    United States
    Austria
    Belgium
    Bulgaria
    France
    Germany
    Hungary
    Italy
    Poland
    Romania
    Spain
    United Kingdom
    Czechia
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 150
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1250
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 600
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Adolescents
    Adolescenti
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state70
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 800
    F.4.2.2In the whole clinical trial 2000
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No interventions will be dispensed after the end of the study unless the participant enters the open-label brazikumab study (Study 3150-303- 008).
    Non verranno erogati interventi dopo la fine dello studio a meno che il partecipante non entri nello studio in aperto di brazikumab (Studio 3150-303-008).
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-09-03
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-06-26
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 18:02:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA